APS, Pfizer IGLC Partner to Fund Chronic Pain Research

Share this content:
APS has partnered with Pfizer IGLC to enhance care for individuals with chronic pain by allocating up to $2 million in funding for research grants.
APS has partnered with Pfizer IGLC to enhance care for individuals with chronic pain by allocating up to $2 million in funding for research grants.

With 100 millions Americans living with chronic pain, the medical community is continuing its efforts to improve the care of patients experiencing this condition. 

The American Pain Society (APS) has partnered with Pfizer Independent Grants for Learning and Change (IGLC) to enhance care for individuals with chronic pain by allocating up to $2 million in funding for research grants. 

TRENDING ON CPA: Interventional Pain Management: 5 Things Primary Care Providers Should Know 

"With a diverse mission to advance the treatment of pain from multiple perspectives, the American Pain Society strongly supports the goals of the National Pain Strategy to increase funding for pain research and we are pleased to partner in this grant funding initiative," APS President Gregory Terman, MD, PhD, said in a statement. 

APS and Pfizer IGLC are seeking to finance proposals that cover one of six domains identified in the National Pain Strategy: population research, prevention and care, disparities, service delivery and payment, professional education and training, and public education and communication.

An APS Scientific Review Panel will review and evaluate recommendations for the award. With Pfizer funding the awards, the APS Steering Committee will make final grant decisions.

Primary care professional associations, academic medical centers, health care systems and other inter-professional organizations are eligible to submit grant proposals.

You must be a registered member of Clinical Pain Advisor to post a comment.